Literature DB >> 15606611

Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses.

A Hasebe1, S M F Akbar, S Furukawa, N Horiike, M Onji.   

Abstract

The chronic hepatitis B virus (HBV) carrier exhibits ongoing replication of HBV and expresses abundant amounts of HBV-related antigens in the liver. However, HBV-specific immune responses are either absent or narrowly focused in these subjects. With the postulation that impaired functional abilities of liver dendritic cells (DCs) might be responsible for this, we assessed the functions of liver DCs in HBV transgenic mice (HBV-TM), an animal model of the HBV carrier state. Liver DCs were isolated from normal C57BL/6 mice and HBV-TM without the use of cytokines or growth factors. Lymphoproliferative assays were conducted to evaluate the ability of liver DCs to induce the proliferation of allogenic T lymphocytes and hepatitis B surface antigen (HBsAg)-enriched T lymphocytes. Liver DCs were stimulated with viral and bacterial products to assess their cytokine-producing capacities. In comparison to liver DCs from normal C57BL/6 mice, liver DCs from HBV-TM exhibited significantly decreased T cell proliferation-inducing capacities in allogenic mixed leucocyte reaction (P <0.05) and HBsAg-enriched T lymphocytes proliferation assays (P <0.05). Liver DCs from HBV-TM produced significantly lower levels of interleukin-12p70, tumour necrosis factor-alpha, interferon-gamma, and interleukin-6 (P <0.05) compared to liver DCs from normal C57BL/6 mice. This study provides evidence that liver DCs from HBV-TM had impaired ability to induce both innate and adaptive immune responses. This might account for a weak and almost undetectable HBV-specific immune response in chronic HBV carriers. This inspires hope that up-regulation of the functions of liver DCs in situ may have therapeutic implications in chronic HBV carriers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606611      PMCID: PMC1809262          DOI: 10.1111/j.1365-2249.2005.02676.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 2.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

3.  Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.

Authors:  C Bain; A Fatmi; F Zoulim; J P Zarski; C Trépo; G Inchauspé
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

4.  Expression and replication of hepatitis B virus genome in transgenic mice.

Authors:  K Araki; J Miyazaki; O Hino; N Tomita; O Chisaka; K Matsubara; K Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

5.  Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.

Authors:  S M Akbar; M Abe; T Masumoto; N Horiike; M Onji
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

Review 6.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 7.  Vaccine therapy for hepatitis B virus carrier.

Authors:  Sk Md Fazle Akbar; Shinya Furukawa; Norio Horiike; Morikazu Onji
Journal:  Curr Drug Targets Infect Disord       Date:  2004-06

8.  Interleukin-10 secretion differentiates dendritic cells from human liver and skin.

Authors:  Sarah Goddard; Janine Youster; Emma Morgan; David H Adams
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 9.  Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis.

Authors:  F V Chisari
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

10.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Matthew L Albert; Charles M Rice
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

View more
  11 in total

1.  Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis.

Authors:  Carlo Selmi; Angela Ceribelli; John M Vierling
Journal:  Semin Immunopathol       Date:  2012-12-19       Impact factor: 9.623

Review 2.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

3.  Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus.

Authors:  S Chen; S M F Akbar; M Abe; Y Hiasa; M Onji
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

4.  Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B.

Authors:  Ning Xu; Hang-Ping Yao; Guo-Cai Lv; Zhi Chen
Journal:  Inflamm Res       Date:  2012-06-10       Impact factor: 4.575

5.  New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response.

Authors:  Dilip Ratnam; Kumar Visvanathan
Journal:  Hepatol Int       Date:  2008-02-27       Impact factor: 6.047

6.  He Jie Tang in the treatment of chronic hepatitis B patients.

Authors:  Ze-Xiong Chen; Shi-Jun Zhang; Shao-Xian Lao; Hong-Tao Hu; Cui-Yi Zhang; Shi-He Guan; Yan-Li Gu
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

7.  Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection.

Authors:  Peng-Yuan Zheng; Dong-Yun Zhang; Gao-Feng Lu; Ping-Chang Yang; Yuan-Ming Qi; Bai-Sheng Wang
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

8.  Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B.

Authors:  Gao-Feng Lu; Fu-Ai Tang; Peng-Yuan Zheng; Ping-Chang Yang; Yuan-Ming Qi
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

9.  Expression of ICAM-1, HLA-DR, and CD80 on peripheral circulating CD1 alpha DCs induced in vivo by IFN-alpha in patients with chronic hepatitis B.

Authors:  Yong-Sheng Yu; Zheng-Hao Tang; Jing-Chao Han; Min Xi; Jie Feng; Guo-Qing Zang
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

10.  Impaired dendritic cell functions because of depletion of natural killer cells disrupt antigen-specific immune responses in mice: restoration of adaptive immunity in natural killer-depleted mice by antigen-pulsed dendritic cell.

Authors:  O Yoshida; F Akbar; T Miyake; M Abe; B Matsuura; Y Hiasa; M Onji
Journal:  Clin Exp Immunol       Date:  2008-02-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.